Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Bio Co., Ltd.

Hiromasa Miyaji

Seiga Itoh

Nobuo Hanai

Motoo Yamasaki

Kenya Shitara

Makoto Morimoto

Kazuo Yamaguchi

Moriyuki Sato

Yoshiharu Yokoo

Yoshihisa Kuwana

Mamoru Hasegawa

Masami Okabe

Tetsuro Kuga

Yoshinori Komatsu

Hajime Yoshida

Yusuke Nakamura

Toshio Ota

Sumio Sugano

Hiroyuki Nagata

Ayako Kawabata

Motoko Haruoka

The present invention relates to a novel phospholipase Apolypeptide, DNA encoding the polypeptide, a vector comprising the DNA, a transformant transformed with the vector, and a process for producing the phospholipase Apolypeptide. The present invention also relates to a method of utilizing the polypeptide, e.g., a method of screening for a compound having agonist or antagonist activity by using the polypeptide or an antibody to the polypeptide, and a pharmaceutical comprising the polypeptide or an antibody to the polypeptide. The present invention further relates to a polypeptide inhibiting the phospholipase Aactivity of a phospholipase Apolypeptide (hereinafter referred to as inhibitor polypeptide), DNA encoding the inhibitor polypeptide, a vector comprising the DNA encoding the inhibitor polypeptide, a transformant transformed with the vector, a pharmaceutical comprising the inhibitor polypeptide, and a process for producing the inhibitor polypeptide.

[object Object]

A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3

A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.

Process for producing humanized chimera antibody

Polypeptide composing human chimeric antibody

Human chimeric antibody specific for the ganglioside GD3

Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.

G-CSF conjugate

Method of producing a polypeptide having human granulocyte colony

A humanized chimera antibody, a process for its production and methods for its use are disclosed. The chimera antibody is produced without changing any amino acids of its mouse antibody variable region.

Method of treating cancer using a chimera antibody

Polypeptide derivatives of human granulocyte colony stimulating factor

DNA encoding human granulocyte colony stimulating factor plasmids and

Growing community of inventors

Tokyo, Japan

Hiromasa Miyaji